Oncora Medical is a technology company.
Oncora Medical has raised $4.0M across 2 funding rounds.
Oncora Medical has raised $4.0M in total across 2 funding rounds.
Oncora Medical is a Philadelphia-based digital health company founded in 2014 (with some sources noting 2015) that builds an AI-powered oncology software platform to improve cancer patient outcomes.[1][2][3][5] It serves cancer care centers, radiation oncologists, physicians, and researchers by streamlining data integration, documentation, treatment decision-making, and research through tools like Oncora Patient Care™, Oncora Analytics™, AI scribes, cancer registry automation, and revenue cycle management.[1][2][3][7] The platform solves key problems in oncology care, including fragmented data from EHRs, PACS, and registries; excessive documentation burden; and inefficient outcome prediction, enabling predictive modeling, real-world data analytics, and workflow automation that has reduced documentation time by 75% and boosted revenue capture by 90% in implementations.[1][3] Oncora has gained traction at top U.S. cancer centers, including collaborations with MD Anderson and Varian, reflecting strong growth in precision medicine.[1]
Oncora Medical emerged from the need to transform scattered cancer patient data into actionable insights for better radiation oncology treatments.[4][5] Founded in 2014 in Philadelphia, Pennsylvania, the company was driven by a mission to help physicians and scientists leverage real-world data, with early development of its Oncora Patient Care™ solution in collaboration with MD Anderson Cancer Center.[1][2] This partnership marked a pivotal moment, capturing treatment and outcome data to fuel predictive modeling.[1] By integrating with major EHRs, PACS, and registries, Oncora quickly addressed core pain points in clinical decision-making, evolving from data integration to a full AI suite including analytics and automation, now trusted by leading healthcare organizations worldwide.[1][3]
Oncora stands out in oncology software through its end-to-end AI platform tailored for radiation oncology and broader cancer care:
Oncora rides the wave of AI-driven precision oncology, where real-world evidence and automation address surging cancer care demands amid clinician shortages and regulatory pushes for data-driven decisions.[1][3] Timing is ideal as healthcare shifts to value-based care, with AI reducing administrative burdens (e.g., EHR fatigue) and enabling personalized radiation treatments—critical as global cancer cases rise.[1][2] Market forces like EHR interoperability mandates and precision medicine investments favor Oncora's integrations and predictive tools, positioning it to influence ecosystem standards through partnerships with giants like Varian and MD Anderson.[1] By aggregating anonymized real-world data, it accelerates research, outpacing imaging-focused rivals and contributing to broader AI adoption in healthcare.[2]
Oncora Medical is poised for expansion as AI oncology tools become essential, with next steps likely including global scaling, deeper EHR integrations, and advanced multimodal AI for immunotherapy and multi-omics data.[1][3] Trends like generative AI for clinical notes, federated learning for privacy-preserving datasets, and payer demands for outcome predictions will propel growth, potentially through acquisitions or IPO amid digital health funding rebounds. Its influence may evolve from workflow enhancer to oncology data leader, empowering more centers to deliver precision care and setting benchmarks for AI in high-stakes medicine—ultimately fulfilling its founding promise to revolutionize cancer treatment outcomes.[1][3]
Oncora Medical has raised $4.0M in total across 2 funding rounds.
Oncora Medical's investors include BioAdvance, GIT1K.
Oncora Medical has raised $4.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in September 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2017 | $3.0M Seed | BioAdvance | |
| Mar 1, 2016 | $1.0M Seed | BioAdvance, GIT1K |